MS
TYRA icon

Maven Securities’s Tyra Biosciences TYRA Stock Holding History

Maven Securities’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,140
Closed -$178K – 1155
2021
Q3 		$178K Buy
+10,140
New +$194K 0.01% 971

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $76.1M AUM 638.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Maven Securities's TYRA Position: Q4 2021 in Review

Maven Securities sold out of Tyra Biosciences (TYRA) in Q4 2021, closing a stake of 10,140 shares — an estimated $178K sold.

Maven Securities first reported a position in TYRA in Q3 2021 and held it in 1 quarter. The position peaked at $178K in Q3 2021. 45 funds tracked by Wall St. Rank hold TYRA as of Q4 2021.

  • Maven Securities reported no remaining Tyra Biosciences position as of Q4 2021 after selling out during the quarter.
  • Maven Securities sold 10,140 Tyra Biosciences shares in Q4 2021, an estimated $178K.
  • Maven Securities first reported a position in Tyra Biosciences in Q3 2021 and held it in 1 quarter.
  • Maven Securities's Tyra Biosciences position peaked at $178K in Q3 2021.
  • 45 funds tracked by Wall St. Rank held Tyra Biosciences as of Q4 2021.

Based on Maven Securities's 13F filing for Q4 2021, filed 14 Feb 2022.